Test Price
2,800 AEDโ Home Collection Available
SIX1 Gene Deafness (Autosomal Dominant Type 23) Genetic Test in UAE โ 2,800 AED โ DHA Licensed Reference Lab
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015 accredited NGS processing (Cert: INT/EGQ/2509DA/3139).
- Collection Logistics: VIP Mobile Phlebotomy and temperature-controlled cold-chain home collection available daily 8 AM to 11 PM.
- Post-Test Support: Complimentary telephonic guidance from a DHA-licensed genetics professional for result interpretation.
- Insurance Verification: Direct billing confirmation via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SIX1 gene sequencing test detects pathogenic variants in the SIX1 gene responsible for autosomal dominant deafness type 23 (DFNA23). This non-syndromic hearing loss typically presents in childhood or early adolescence. Our laboratory employs whole-gene sequencing with deletion and duplication analysis to deliver a definitive molecular diagnosis.
| Feature | SIX1 NGS (DNA Labs UAE Reference Lab) | Targeted Genotyping Panel (Alternative) |
|---|---|---|
| Scope | Full gene sequencing and deletion/duplication analysis | Known founder and point mutations only; novel variants missed |
| Platform | Illumina NovaSeqโข with 300x mean coverage; Sanger confirmed | PCR-based allelic discrimination |
| Turnaround Time | 3โ4 weeks | 2โ3 weeks (limited detection range) |
Physician Insight & Safety Protocols
โIdentifying a pathogenic SIX1 variant provides clarity for a child's hearing loss and enables early intervention with cochlear implants or hearing aids. However, genetic results must always be interpreted alongside audiometric data and clinical examination. A negative result does not eliminate environmental or other hereditary causes. I am available to discuss the full auditory and family history before and after testing.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Guidance โ Medication and Device Use
Important Clinical Note: Do not alter or discontinue any prescribed hearing aids, cochlear implant settings, or systemic medications based solely on this genetic test result. All treatment decisions require a comprehensive evaluation by your otolaryngologist and genetic specialist.
Exclusion Criteria & Emergency Red Flags
- Active middle-ear infection or recent otologic surgery โ defer collection until fully resolved.
- Inability to obtain informed consent from the patient or legal guardian (minors require signed consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability).
- Emergency indicators: sudden hearing loss within 72 hours, acute vertigo with nystagmus, or focal neurological deficits โ proceed to emergency care before elective testing.
Patient FAQ & Clinical Guidance
1. What sample is required, and can a phlebotomist visit my home?
A peripheral whole blood sample (3โ5 mL in an EDTA tube), one drop on an FTA card, or extracted DNA is accepted. Our DHA-licensed mobile phlebotomist can collect at your residence between 8 AM and 11 PM daily. The specimen is transported under temperature-controlled cold-chain conditions to preserve nucleic acid integrity.
2. When will I receive results, and who explains them?
Results are issued within 3 to 4 weeks from sample receipt. A complimentary post-test teleconsultation with a DHA-registered genetics professional is included to review the report and recommend next steps. Variants are classified per ACMG guidelines (Pathogenic, Likely Pathogenic, or Variant of Uncertain Significance).
3. Is insurance accepted, and can I have pre-test genetic counselling?
Most UAE insurers cover genetic hearing loss testing when medically indicated. We verify your coverage instantly via WhatsApp. Pre-test genetic counselling to construct a three-generation pedigree and discuss inheritance patterns is strongly recommended and can be arranged before sample collection. All genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
UAE Regulatory & Data Privacy Adherence
Data Protection Framework: All patient genetic data is processed exclusively under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Laboratory operations are ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139) and fully compliant with DHA Facility License No. 1143.
Clinical & Logistical Metadata
| Test Name | SIX1 Gene Deafness (Autosomal Dominant Type 23) Genetic Test โ NGS Full Gene Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card โ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection Available Daily (8 AM โ 11 PM) |
| Methodology Used | Next-Generation Sequencing (Illumina NovaSeqโข, 300x mean coverage) with Sanger confirmation of variants; deletion/duplication analysis included |
| ICD-10-CM Code | H90.5 |
| LOINC Code | 81247-9 |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians